Munich, November 21, 2022 - neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practice,
Alzheimer's disease causes significant suffering in those affected and their caregivers. Currently, there is no known cure for the disease and the underlying causes are not fully understood. However
As we close off ADHD Awareness month we have taken the chance to speak to one of our clinicians from the Netherlands - Drs. Joris van Neijenhof who has been working with patients with ADHD for a
Our training courses are designed to instruct clinicians, academics and researchers in the use of neuromodulation technology, with a goal to apply these techniques in clinical practices or research settings. Under the guidance of our expert trainers, students receive substantial hands-on experience with rTMS, tDCS and neurofeedback technology and its application. Over the last 10 years we have trained more than 1,000 professionals from over 30 countries in the use of neuromodulation techniques. We have continually received outstanding feedback from our trainees, with an average evaluation of 8.9/10.
For more than ten years the neuroConn brand has been associated with practice-oriented medical technology used in neuroscience and clinical research, as well as in the diagnosis and treatment of neuropsychological disorders. In close cooperation with leading research institutions and clinics worldwide, neuroConn technology is designed following the latest medical research standards. In this way we provide users with standardised and clinically evaluated protocols in transcranial Electrical Stimulation (tDCS, tACS, tRNS) as well as Neurofeedback of Slow Cortical Potentials.
